Precigen (NASDAQ:PGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Precigen (NASDAQ:PGEN) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Several other equities analysts also recently weighed in on PGEN. Citizens Jmp lifted their target price on shares of Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 26th. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Finally, HC Wainwright boosted their target price on shares of Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.50.

Precigen Stock Down 11.4%

Shares of NASDAQ PGEN opened at $3.25 on Friday. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 2.83. The stock has a market capitalization of $1.15 billion, a PE ratio of -2.43 and a beta of 1.10. Precigen has a one year low of $1.11 and a one year high of $5.47. The business’s fifty day moving average price is $4.06 and its 200-day moving average price is $3.97.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $4.57 million during the quarter, compared to analyst estimates of $8.29 million. On average, equities research analysts anticipate that Precigen will post -0.32 EPS for the current year.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently bought and sold shares of PGEN. Xponance LLC boosted its holdings in Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,496 shares during the period. BNP Paribas Financial Markets grew its position in shares of Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares in the last quarter. Composition Wealth LLC boosted its stake in Precigen by 16.5% during the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,000 shares during the period. Intech Investment Management LLC boosted its stake in Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 3,137 shares during the period. Finally, Strs Ohio grew its position in Precigen by 6.8% during the third quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,200 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.